Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/13/2008 - (DGNews)
    Declining Benefit of Combination Therapy for Rheumatoid Arthritis Found in Long-Term Follow-Up of Patients: Presented at ACR-ARHP - (DGDispatch)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Efficacy of Rituximab Is Sustained in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Tocilizumab Is Effective for Rheumatoid Arthritis in Patients With Inadequate Response to Prior Anti-TNF Treatment: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      The Management of Difficult Rheumatoid Arthritis
      Expanding the Armamentarium for the Treatment of Juvenile Rheumatoid Arthritis: Update for Managed Care Pharmacists
      Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Aggressive Combination Therapy Reduces Risk of Heart Attack by 80% in People with Rheumatoid Arthritis

        ATLANTA, GA -- November 14, 2007 -- The use of combination tumor necrosis factor alpha (TNF)-inhibitor-methotrexate therapy in people with rheumatoid arthritis was associated with a risk of heart attack that was reduced by 80% in comparison with those using methotrexate alone, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Boston, Mass.

        Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of many joints. An estimated 2.1 million Americans have RA, most of them women. Although joints are the principal body parts affected by RA, inflammation can develop in other organs as well. Heart attacks, resulting from inflammation of the coronary vessels, are more common in RA sufferers.

        Researchers recently studied the risk of heart attack in patients using a TNF-inhibitor (a drug that blocks cytokines and can reduce pain, morning stiffness and swollen joints in RA), methotrexate (a drug used to treat RA by blocking the metabolism of cells) and other disease modifying antirheumatic drugs (DMARDs) in a large population of patients with RA -- many of whom were also taking aspirin.

        Using data obtained from MediCal, California's Medicaid program, researchers studied patients over the age of 18, suffering from RA, who were treated with TNF-inhibitors, methotrexate, or other DMARDs, over six-and-a-half years.

        A total of 19,233 patients with RA were identified. The patients' mean age was 55 years, and approximately 79% were women. Of these patients, 13,383 took methotrexate; 14,958 took other DMARDS; and 4,943 took TNF-inhibitors. Exposure to TNF-inhibitors (taken alone or in combination with methotrexate) was compared to taking methotrexate alone.

        During the study period, 441 patients suffered heart attacks, of which 8% were fatal.

        Researchers found that patients on a combination of TNF-inhibitors with methotrexate treatment had a heart attack risk of only 20% of the risk compared to patients taking methotrexate alone.

        However, there was no statistical difference seen among patients who were taking TNF-inhibitors alone, TNF-inhibitors with other DMARDs, other DMARD therapies without methotrexate, or a combination of DMARDs and methotrexate.

        "TNF-inhibitor therapy, in combination with methotrexate, dramatically reduces the risk of heart attacks in patients with RA and should be seriously considered -- especially in high-risk patients," said Gurkirpal Singh, MD; adjunct clinical professor of medicine, division of gastroenterology and hepatology, Stanford University School of Medicine; chief science officer, Institute of Clinical Outcomes Research and Education; and an investigator in the study.


        SOURCE: American College of Rheumatology



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send